Innate Pharma presents initial Phase 1 clinical data for IPH4502 at ENA 2026

On November 18, 2026 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported initial Phase 1 data from its ongoing study of IPH4502, an investigational Nectin-4-targeting antibody-drug conjugate (ADC) incorporating an exatecan payload, in patients with advanced solid tumors. The results are being presented today at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The Phase 1 findings provide an encouraging foundation for the continued development of IPH4502," said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. "The observed antitumor activity and safety profile strengthen our commitment to advancing this program, particularly for patients with urothelial cancer previously treated with enfortumab vedotin, where significant unmet need remains. Our focus now is on optimizing the dose and schedule to further characterize antitumor activity and tolerability in this setting and inform selection of a recommended Phase 2 regimen."

Study Population and Background
The Phase 1 dose-escalation study of IPH4502 enrolled 76 patients with advanced solid tumors across six dose levels ranging from 0.6 mg/kg to 3.6 mg/kg, administered once every three weeks. Patients were heavily pretreated, with a median of 3.5 prior lines of systemic therapy and represented more than 10 tumor types. Nineteen patients had urothelial cancer (UC), all of whom had previously received PADCEV (enfortumab vedotin). The primary objective of the study was to assess the safety and tolerability of IPH4502, while secondary objectives include evaluating its pharmacokinetics and antitumor activity in patients with advanced solid tumors.

Safety and Tolerability
As of the August 17, 2026 data cutoff, IPH4502 was well-tolerated during Phase 1 dose escalation, with low overall hematologic toxicity.

•The maximum tolerated dose was established at 3.6 mg/kg administered once every three weeks, with stomatitis as the only reported dose-limiting toxicity. No febrile neutropenia or hematologic dose-limiting toxicities were reported, and no signal of peripheral neuropathy was observed.
•Grade 3 or higher treatment-emergent adverse events (TEAEs) were reported in 43.4% of patients, including Grade 3 or higher anemia in 11.8%. Stomatitis occurred in 27.6% of patients overall, including 3.9% with Grade 3 or higher events.
•TEAEs led to dose reductions in 7.9% of patients and treatment discontinuations in 5.3%.
Antitumor Activity
As of the August 17, 2026 data cutoff, antitumor activity (measured using RECIST v1.1 criteria) was observed across multiple dose levels, tumor types and Nectin-4 expression levels.

•Objective responses were observed in patients in several tumor types and across low, moderate and high Nectin-4 expression levels.
•At the maximum tolerated dose of 3.6 mg/kg, an objective response rate (ORR) of 33% (2/6)[1] was observed in patients with non-urothelial tumors.
•In urothelial cancer, 19 patients were enrolled, with a median of three prior lines of systemic therapy; all had previously received enfortumab vedotin. Out of these 19 patients, 15 were enrolled at 2.4 or 2.8 mg/kg, 4 at 3.2 mg/kg and none at 3.6 mg/kg (MTD). At these intermediate dose levels, antitumor activity was observed, with 3 partial responses (1confirmed and 2 unconfirmed partial responses) and tumor shrinkage in the majority of patients. The unconfirmed disease control rate [95%CI] was 68.4% [46.0 – 84.6].

Future Clinical Development Strategy
Phase 1 dose optimization is being initiated in second-line or later urothelial cancer following enfortumab vedotin, to further characterize safety and activity in post-EV urothelial cancer at upper dose levels. The first patient is planned in the first half of 2027. The study will evaluate split dosing on Days 1 and 8 of each three-week cycle with mandatory prophylaxis to help reduce stomatitis and inform selection of a recommended Phase 2 dose and schedule.

ENA Presentation and KOL Event
Following the Phase 1 IPH4502 data being presented at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics on November 18, 2026, Innate will host an in-person and virtual key opinion leader (KOL) event the same day, at 11:00 a.m. ET / 4:00 p.m. GMT to discuss the results, their clinical context and the planned next steps of IPH4502 development (press release). The event will take place at IET London: Savoy Place, with a live webcast available through the following registration link: View Source

About IPH4502
IPH4502 is Innate Pharma’s proprietary Nectin-4 antibody-drug conjugate (ADC), built on three differentiated components. The payload is exatecan, a potent topoisomerase I inhibitor, with the potential to overcome key limitations associated with monomethyl auristatin E (MMAE)-based ADCs, including multidrug resistance protein 1 (MDR1)-mediated resistance. IPH4502 incorporates a proprietary stable linker designed to slow the release of free exatecan into the circulation in order to improve tolerability. The binder is a proprietary humanized anti-Nectin-4 antibody with high affinity and a distinct, non-overlapping epitope compared with enfortumab vedotin (EV). IPH4502 is currently being evaluated in the Phase 1 IPH4502-101 study (NCT06781983) in patients with advanced solid tumors known to express Nectin-4. Initial clinical data from the Dose escalation phase (ENA 2026 poster) showed antitumor activity across multiple tumor types, including urothelial cancer previously treated with enfortumab vedotin, alongside an encouraging tolerability profile with low overall hematologic toxicity. Phase 1 dose optimization is being initiated in second-line or later urothelial cancer following enfortumab vedotin.

IPH4502 is currently under clinical development and has not received marketing authorization in the European Union or approval from the U.S. Food and Drug Administration (FDA). Its safety and efficacy have not been established for any commercial use. The product is not available for commercial distribution.

(Press release, Innate Pharma, NOV 18, 2026, View Source [SID1234674912])

Providence Therapeutics Enrolls First Patient in World’s First Clinical Trial of a Personalized mRNA Vaccine for Pediatric Brain Cancer

On November 18, 2026 Providence Therapeutics, Inc., a clinical-stage biotechnology company specializing in messenger RNA (mRNA) vaccines, reported that enrolment has started for the PaedNEO-VAX clinical trial, a world-first study evaluating personalized mRNA cancer vaccines for children and young adults with aggressive and treatment-resistant brain tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Providence Therapeutics’ CEO, Brad Sorenson, commented, "The PaedNEO-VAX marks a significant milestone for Providence’s PTX-108 personalized mRNA cancer vaccine program as a new treatment option for pediatric brain cancer patients. Providence remains committed to advancing therapies for both active and measurable solid tumors as well as patients with minimal residual disease."

The PaedNEO-VAX trial is in collaboration with the Australia and New Zealand Children’s Hematology/Oncology Group (ANZCHOG), that will bring Providence’s PTX-108 to eight pediatric hospitals across Australia and New Zealand. The trial is funded through the Australian Government’s Medical Research Future Fund, alongside contributions from philanthropic partners.

Pediatric brain cancer is a devastating disease that represents one of the highest unmet medical needs in modern medicine. PTX-108 seeks to address the uniqueness of each patient’s tumor by producing an individual vaccine designed based on the antigen profile of the tumor. The vaccine is designed to stimulate the patient’s immune system to recognize and attack their cancer cells.

The trial includes children and young adults with high-risk brain tumors, including relapsed or refractory high-grade gliomas, diffuse midline gliomas, medulloblastomas, and ependymomas. The Phase 1 portion of the study will evaluate the safety and tolerability of PTX-108 and establish a recommended dose for the Phase 2 portion of the trial that may serve as a basis for submission for regulatory approval. Providence plans to expand the development of PTX-108 in additional regions to bring this novel treatment to patients around the world.

The trial leverages data collected through the ZERO Childhood Cancer initiative, which represents the world’s most comprehensive precision medicine program and database of whole genome sequencing data for children and young people with cancer. The study evaluating PTX-108 is sponsored by ANZCHOG and co-led by researchers at the University of Queensland and the South Australian Health and Medical Research Institute (SAHMRI), in collaboration with QIMR Berghofer. The initiative is supported by funding from the Australian Government’s Medical Research Future Fund (MRFF), the Robert Connor Dawes (RCD) Foundation, the Marcus Rosin Fund, and the Children’s Cancer Foundation, alongside contributions from Providence Therapeutics.

According to Brandon Wainwright, Director and CEO of QIMR Berghofer, "The PaedNEO-VAX trial underscores a commitment to advancing personalized mRNA medicines to cancer patients who lack effective treatment options. We are excited to collaborate with ANZCHOG and with Providence to leverage their mRNA cancer vaccine platform and the trove of information encompassed in the ZERO database to bring this promising new treatment approach to children with a range of brain cancers."

(Press release, Providence Therapeutics, NOV 18, 2026, View Source [SID1234674928])

Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development

On November 17, 2026 Cancer Research UK and Dewpoint Therapeutics reported a collaboration and licence agreement to advance DPTX8743, a potential first-in-class small molecule modulator of MYC condensates, into clinical development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) is responsible for funding, sponsoring and executing a first-in-human Phase 1/2a clinical trial of DPTX8743, including Clinical Trial Application (CTA)-enabling studies. Dewpoint retains all rights to DPTX8743 and has the right to license the results and intellectual property arising from the collaboration, with Cancer Research UK eligible to receive downstream milestone payments and royalties. Cancer Research Horizons, Cancer Research UK’s innovation arm, will manage the commercial relationship between Cancer Research UK and Dewpoint.

The collaboration represents an important step toward advancing a novel therapeutic approach to addressing MYC, one of oncology’s most validated yet historically difficult-to-drug targets, into clinical evaluation.

DPTX8743 targets MYC biology through a novel mechanism designed to disrupt the transcriptional condensates that drive MYC-dependent gene expression. In preclinical models, DPTX8743 has demonstrated the ability to disrupt these condensates, suppress MYC-driven gene expression and induce tumour cell death.

MYC is a critical driver of cancer, with abnormal MYC activity implicated in the majority of human cancers. Despite decades of research, MYC has proven extremely difficult to target and has historically been considered undruggable. By targeting the molecular processes that enable MYC activity, DPTX8743 has the potential to provide a new therapeutic approach for people with MYC-driven cancers, including ovarian, oesophageal, colorectal and pancreatic cancers.

Lars Erwig, Director of the CDD, said: "MYC is one of the most important drivers of cancer, but it is notoriously difficult to target with drugs. DPTX8743 takes an innovative approach by targeting the condensate biology underlying MYC activity rather than the protein directly. We’re excited to work with Dewpoint to advance this promising candidate into Phase 1/2a development and investigate its potential for people with cancer."

Ameet Nathwani, Chief Executive Officer of Dewpoint Therapeutics, said: "We are delighted to partner with Cancer Research UK, whose Centre for Drug Development brings world-class scientific and clinical expertise to advance DPTX8743 towards clinical proof of concept. Building on our clinical stage β-catenin programme, DPTX8743 extends our condensate approach to MYC, one of oncology’s most important and historically challenging targets. This collaboration reinforces our conviction that condensate modulation can unlock new therapeutic possibilities for patients with significant unmet medical need."

(Press release, Cancer Research UK, NOV 17, 2026, View Source [SID1234674845])

Laboratoires Pierre Fabre : FDA Fast Track designation for elticertinib in NSCLC

On November 17, 2026 Laboratoires Pierre Fabre reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to elticertinibi (also known as PFL-721 previously STX-721), for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") harboring EGFR exon 20 insertion mutations, whose disease has progressed on both platinum-based chemotherapy and amivantamab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The FDA’s fast track designation is designed to expedite the development and review of therapies to treat serious conditions with significant unmet medical needs. The designation has been granted based on nonclinical data as well as preliminary efficacy data from the ongoing Phase 1/2 clinical trial (NCT06043817). It provides Laboratoires Pierre Fabre with increased opportunities for interaction with the FDA, as well as eligibility for rolling and priority review, if relevant criteria are met.

Elticertinib is a highly differentiated, orally bioavailable, irreversible highly selective investigational tyrosine kinase inhibitor ("TKI") targeting epidermal growth factor receptor ("EGFR") and ERBB2 (HER2) Exon 20 insertion ("ex20ins") mutations.

NSCLC is the most common sub-type of lung cancer and various EGFR mutations are the most frequent drivers of NSCLC, occurring in up to 38% of tumors, depending on geography.ii,iii,iv Of this population, up to 10% have ex20ins mutations.

"This fast-track designation is a first for Laboratoires Pierre Fabre, and a significant milestone that reflects the strength and maturity of our R&D capabilities in oncology. It confirms our ability to bring innovative, highly differentiated therapies from research to patients, and strengthens our ambition to become a recognized global player in precision oncology," said Eric Ducournau, Chief Executive Officer of Laboratoires Pierre Fabre.

"This designation underscores the urgent need for new treatment options for patients with EGFR ex20ins-mutated NSCLC, who still face limited efficacy and significant tolerability challenges with currently available therapies. It will allow us to engage more closely with the FDA to accelerate elticertinib development and bring this targeted therapy to patients faster" said Marie-Andrée Gamache, Laboratoires Pierre Fabre Pharma Chief Executive Officer.

(Press release, Pierre Fabre, NOV 17, 2026, View Source;fda-fast-track-designation-for-elticertinib-in-nsclc-302941043.html [SID1234674893])

Avenor Therapeutics Secures Two Deals to Unlock Heat-Activated Precision Oncology, Uniting a Hyperthermia System and Thermosensitive Drug Platforms Under One Roof

On November 17, 2026 Avenor Therapeutics reported it has secured the two assets at the heart of its strategy:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

*ALBA, the best-in-class hyperthermia system already treating patients across Europe and Asia; and
*a next-generation of heat-activated tumor targeting drug platform with a Phase II-ready lead candidate.
Two deals, one strategy.

Avenor secured, through a strategic partnership, exclusive North American rights to ALBA, a CE-marked radiative precision hyperthermia platform developed by Medlogix Srl (Rome, Italy), with 74+ systems installed to date across Europe and Asia and a track record in daily clinical use.

Avenor also signed an exclusive worldwide license agreement with Thermosome GmbH (Munich, Germany). This agreement covers the thermosensitive liposome (TSL) technology: the Phase II-ready lead candidate THE001, with FDA and EMA Orphan Drug Designation for soft tissue sarcoma, and the entire TSL platform portfolio, with a defined path to full ownership.

Financial terms of the deals were not disclosed.

Together, these transactions position Avenor with a uniquely integrated platform, combining planned, measured heat delivery to the tumor with a thermosensitive drug technology engineered to release its payload precisely at the site of thermal activation.

Global reach. More than a drug. More than a device.

Avenor brings to North America, for regulatory approval and commercialization, a hyperthermia device already in daily clinical use across Europe and Asia. On the drug side, Avenor holds worldwide rights to clinical-stage heat-activated therapeutics, led by THE001, and to the thermosensitive liposome platform behind them, designed so that cancer therapies are activated, enhanced and directed to the tumor. With Avenor, this platform can now be developed globally, across the United States, Europe and Asia.

A committed co-founding and leadership team.

Avenor’s co-founders and leaders unite the people behind both platforms with oncology executives from the US and Europe, committed to delivering innovative solutions to patients:

Patrick Tricoli, PharmD, MBA, Chief Executive Officer
Pierfrancesco Pavoni, Chief Device Officer, founder of Medlogix
Pascal Schweizer, PhD, acting Chief Financial Officer, co-founder of Thermosome
Frank Hermann, MD, acting Chief Medical Officer, leading clinical development
Leonard A. Farber, MD, Chief Medical Affairs and Market Access Officer
Kerstin Pino Tossi, PhD, VP Operations and Business Development
Prof. Lars Lindner, MD, Chair of the Scientific and Medical Advisory Board, co-founder of Thermosome, Sarcoma Center and Hyperthermia lead at LMU University Hospital Munich, Germany.
Patrick Tricoli, Pierfrancesco Pavoni and Pascal Schweizer form the founding Board of Directors of Avenor Therapeutics, Inc.

Early US traction at ASTRO 2026.

At the ASTRO 68th Annual Meeting in Boston (September 26–30, 2026), the Avenor team made its first appearance, introducing ALBA and its thermal-dose escalation approach to the US radiation oncology community. Radiation oncologists, medical physicists and leading US cancer centers engaged with Avenor on how planned, measured heat can add to radiotherapy and showed strong interest in the thermosensitive liposome (TSL) concept of using that heat to release drugs at the tumor. Both were early signs of the US market’s readiness for bringing device and drug together.

"Our vision at Avenor is to harness physics to make heat a precise pillar of cancer care: planned and measured with the same rigor and predictability as radiation, and able to work alongside radiotherapy, chemotherapy, immunotherapy and our own heat-activated drugs," said Patrick Tricoli, Co-founder and CEO of Avenor. "By integrating seamlessly into existing treatment workflows, precision heat has the potential to enhance the effectiveness of cancer therapies while reducing toxicity. We are building the company that brings precision heat-activated oncology to patients."

What comes next.

Avenor is preparing its FDA Pre-Submission to open the regulatory dialogue on ALBA, initiating pricing and reimbursement work for US market access, deepening collaborations with major US institutions that have already expressed interest in its approach, and refining and growing its drug portfolio. Avenor will continue to partner with all stakeholders who support its vision and mission.

(Press release, Avenor Therapeutics, NOV 17, 2026, View Source [SID1234674945])